SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001157523-23-000722
Filing Date
2023-05-04
Accepted
2023-05-04 07:05:27
Documents
13
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 ALDEYRA THERAPEUTICS, INC. 8-K a53393376.htm   iXBRL 8-K 36146
2 EXHIBIT 99.1 a53393376ex99_1.htm EX-99.1 107640
  Complete submission text file 0001157523-23-000722.txt   295275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aldx-20230504.xsd EX-101.SCH 3922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aldx-20230504_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aldx-20230504_pre.xml EX-101.PRE 16042
7 EXTRACTED XBRL INSTANCE DOCUMENT a53393376_htm.xml XML 4233
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 23886397
SIC: 2834 Pharmaceutical Preparations